Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

NCT01211457 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: sapacitabine and decitabine (Part 1 - completed)
DRUG: sapacitabine and venetoclax (Part 2 - recruiting)

Sponsor

Cyclacel Pharmaceuticals, Inc.

Collaborators

[object Object]